Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials-Reference-Cited by-同舟云学术

Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials

Published:2016-12 Issue:6 Volume:75 Page:1156-1161
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Kimball Alexandra B.,Luger Thomas,Gottlieb Alice,Puig Luis,Kaufmann Roland,Nikaï Enkeleida,Zhu Baojin,Edson-Heredia Emily,Carlier Hilde,Lin Chen-Yen,Goldblum Orin,Yosipovitch Gil

Publisher

Elsevier BV

Subject

Dermatology

Reference14 articles.

1. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials;Shikiar;Health Qual Life Outcomes,2003

2. Psoriasis causes as much disability as other major medical diseases;Rapp;J Am Acad Dermatol,1999

3. The effect of severe of psoriasis on the quality of life of 369 patients;Finlay;Br J Dermatol,1995

4. Pruritus is an important factor negatively influencing the well-being of psoriatic patients;Reich;Acta Derm Venereol,2010

5. Differences in itch characteristics between psoriasis and atopic dermatitis patients: results of a web-based questionnaire;O'Neill;Acta Derm Venereol,2011

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond the classic players: Mas‐related G protein‐coupled receptor member X2 role in pruritus and skin diseases;Journal of the European Academy of Dermatology and Venereology;2024-07-23

2. Characteristics and drivers of fatigue in patients with psoriasis and psoriatic arthritis: A cross sectional study;Journal of the American Academy of Dermatology;2024-07

3. Predicting Factors and Clinical Characteristics of Pruritus in Psoriasis: A Cross-Sectional Survey;Life;2024-06-28

4. Properties and Use of the Dermatology Life Quality Index in Patients with Psoriasis;City Healthcare;2023-12-01

5. Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium;Immunotherapy;2023-10